Published in Nat Rev Immunol on September 01, 2002
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A (2003) 3.40
Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol (2010) 3.40
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe (2010) 3.33
From vaccines to memory and back. Immunity (2010) 3.30
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A (2004) 3.23
The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16
The regulation of IgA class switching. Nat Rev Immunol (2008) 2.92
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol (2003) 2.31
HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol (2009) 2.23
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat Rev Immunol (2013) 2.22
Proof of principle for epitope-focused vaccine design. Nature (2014) 2.09
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol (2005) 2.01
Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol (2009) 1.92
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl Acad Sci U S A (2007) 1.89
Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol (2015) 1.82
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol (2003) 1.78
Therapeutic antibodies, vaccines and antibodyomes. MAbs (2010) 1.75
Accelerating next-generation vaccine development for global disease prevention. Science (2013) 1.73
Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope. J Virol (2004) 1.72
HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS (2009) 1.67
How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol (2009) 1.61
Vaccines: the fourth century. Clin Vaccine Immunol (2009) 1.61
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol (2007) 1.56
Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Viruses (2009) 1.54
Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology (2011) 1.53
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A (2007) 1.50
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol (2008) 1.49
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
Computer-aided antibody design. Protein Eng Des Sel (2012) 1.44
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J Virol (2003) 1.43
Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans. Glycobiology (2010) 1.39
Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One (2012) 1.37
Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol (2008) 1.35
A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A (2013) 1.34
Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol (2012) 1.33
Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys. J Virol (2008) 1.30
Recognition of escape variants in ELISPOT does not always predict CD8+ T-cell recognition of simian immunodeficiency virus-infected cells expressing the same variant sequences. J Virol (2007) 1.29
Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci (2011) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. Cell Host Microbe (2009) 1.27
Profiling antibody responses by multiparametric analysis of primary B cells. Proc Natl Acad Sci U S A (2008) 1.25
Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS Negl Trop Dis (2010) 1.25
Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother (2006) 1.25
Somatic Populations of PGT135-137 HIV-1-Neutralizing Antibodies Identified by 454 Pyrosequencing and Bioinformatics. Front Microbiol (2012) 1.24
Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci U S A (2004) 1.23
Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity (2015) 1.23
Antibody neutralization escape mediated by point mutations in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41. J Virol (2005) 1.22
Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. J Immunol (2011) 1.22
The impact of differential antiviral immunity in children and adults. Nat Rev Immunol (2012) 1.21
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods (2006) 1.19
Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33. J Virol (2012) 1.18
B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog (2011) 1.16
Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A (2003) 1.16
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS One (2013) 1.16
Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog (2013) 1.16
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol (2011) 1.13
Experimental rabies vaccines for humans. Expert Rev Vaccines (2010) 1.12
Aberrant localization and underglycosylation of highly accumulating single-chain Fv-Fc antibodies in transgenic Arabidopsis seeds. Proc Natl Acad Sci U S A (2007) 1.12
Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep (2016) 1.11
Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. Virology (2007) 1.11
Importance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response. J Virol (2008) 1.09
Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies. Virology (2007) 1.09
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. J Control Release (2011) 1.05
Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol (2008) 1.05
Immunity to HIV in Early Life. Front Immunol (2014) 1.05
Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol (2006) 1.04
Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol (2012) 1.04
Advances in structure-based vaccine design. Curr Opin Virol (2013) 1.04
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol (2009) 1.02
Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol (2010) 1.01
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob Agents Chemother (2005) 1.00
Essential role for autophagy in the maintenance of immunological memory against influenza infection. Nat Med (2014) 1.00
Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics (2011) 0.99